Variables | Univariate | Multivariate | ||
---|---|---|---|---|
HR(95% CI) | P | HR(95% CI) | P | |
LDH | 4.368(2.010–9.493) | < 0.001 | ||
dNLR | 3.756(1.843–7.657) | < 0.001 | ||
LNI | ||||
LNI(1) | 2.498(1.069–5.836) | 0.035 | 2.063(0.818–5.203) | 0.125 |
LNI(2) | 16.209(5.837–45.011) | < 0.001 | 13.354(4.570–39.025) | < 0.001 |
Age | 1.373(0.591–3.186) | 0.461 | ||
ECOG PS | 2.587(1.302–5.140) | 0.007 | 3.471(1.593–7.562) | 0.002 |
Menstrual status | 0.820(0.379–1.774) | 0.614 | ||
Thrombocytopenia CTCAE grades | 1.515(0.718–3.197) | 0.275 | ||
Treatment lines | 1.062(0.524–2.152) | 0.869 | ||
Liver metastases | 1.574(0.790–3.136) | 0.197 | ||
Brain metastasis | 1.095(0.451–2.658) | 0.841 | ||
HER2 status | 0.172(0.063–0.470) | 0.001 | 0.166(0.051–0.542) | 0.003 |
HR status | 1.382(0.700–2.729) | 0.352 | ||
Number of metastatic sites | 1.360(0.560–3.300) | 0.497 | ||
Prior surgery | 0.761(0.263–2.202) | 0.614 | ||
Trastuzumab plus pertuzumab | 0.812(0.378–1.744) | 0.593 | ||
Anti-HER2 treatment | 0.765(0.315–1.857) | 0.554 | ||
BMC status | 0.761(0.263–2.202) | 0.614 | ||
LDH changing trend | ||||
Down | 0.863(0.399–1.868) | 0.709 | 0.539(0.234–1.240) | 0.146 |
Steady | 0.303(0.110–0.840) | 0.022 | 0.235(0.079–0.701) | 0.009 |
dNLR changing trend | ||||
Down | 1.139(0.523–2.480) | 0.743 | ||
Steady | 0.615(0.256–1.477) | 0.277 |